Literature DB >> 1120392

Disposition of methadone in methadone maintenance.

E Anggård, L M Gunne, J Homstrand, R E McMahon, C G Sandberg, H R Sullivan.   

Abstract

Six detoxified opiate addicts housed in a closed metabolic ward received methadone in stepwise increasing doses of 10, 20, 40, and 80 mg/day during 1 month. Four were given 14C-methadone at the lowest dose and again at the highest dose. Of the subjects receiving radiomethadone, 2 excreted the major part of the radioactivity in urine and 2 about equally in urine and feces. In addition to methadone, 7 metabolites were isolated and identified in urine and 3 metabolites in feces. About 75% of the urinary and fecal radioactive metabolites were unconjugated. Urinary excretion of methadone and its major N-monomethylated metabolite accounted for 17% to 57% of the given dose. The ratio of metabolite to parent drug increased in 5 of 6 subjects, and the urinary recovery of unchanged methadone decreased during the period. The results indicate that enhanced demethylation of methadone may occur during oral administration to man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1120392     DOI: 10.1002/cpt1975173258

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

6.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

Authors:  E Anggård; M I Nilsson; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

Review 9.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

10.  Effect of urinary pH on the disposition of methadone in man.

Authors:  M I Nilsson; E Widerlöv; U Meresaar; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.